Market Overview

Secant Group Announces Collaboration between Orgenesis and Atvio Biotech, a Wholly Owned Subsidiary of Masthercell Global, to Develop and Commercialize Scaffold Technologies for Advanced Cell Therapies

Share:

Secant Group and Atvio Biotech to advance project under $1.8 million
grant from the Israel-U.S. Binational Industrial R&D Foundation

Orgenesis to utilize scaffold technology for its autologous cell
therapy platform

Secant Group, a manufacturer of advanced biomaterials and medical
textiles, today announced collaboration with Orgenesis Inc.
(NASDAQ:ORGS) and Atvio Biotech Ltd., which is wholly-owned by the
Company's Masthercell Global subsidiary, to develop and commercialize
biodegradable and injectable scaffold technologies for use in advanced
cell therapies.

Under the agreement, Secant Group will engineer and prototype 3D
scaffolds based on novel biomaterials and technologies involving
bioresorbable polymer microparticles, while Atvio will provide expertise
in cell coatings, cell production, process development and support
services. The collaboration will be financed in part through a $1.8
million grant from the Israel-U.S. Binational Industrial R&D (BIRD)
Foundation, as well as additional funding provided by Orgenesis and
Secant Group. Orgenesis shall have the right to utilize the technology
for its autologous cell therapy platform, including its Autologous
Insulin Producing ("AIP") cell technology for patients with type 1
diabetes, acute pancreatitis and other insulin deficient diseases.

Vered Caplan, CEO of Orgenesis, commented, "We are encouraged by the
early progress resulting from the collaboration between Atvio and Secant
Group. Secant brings unique expertise in advanced biomaterials and
scaffold structures. Their best-in-class scaffold technology is designed
to minimize stress for the cells thereby potentially enhancing yields
and dramatically shortening cell culturing time. We look forward to
leveraging this technology within our own therapeutic products. This
agreement is closely aligned with our broader strategy to partner and
in-license best-in-class technologies to advance our cell therapy
platform."

Jeff Robertson, President of Secant Group, commented, "Secant Group has
been advancing the use of biomaterials in the field of regenerative
medicine through the development of scaffold technologies for decades.
We are excited to bring our technologies forward in this project.
Biomaterials show significant promise as vehicles for cell
transplantation because of their potential to modulate the
microenvironment of the cells. We believe that their use in 3D
scaffolding of various configurations is gaining substantial acceptance."

About Secant Group:

Secant Group is a global leader in advanced biomaterials and implantable
textile components in support of the medical device and pharmaceutical
industries. Using advanced polymers, metals, and composites Secant Group
develops implantable structures that enable repair, recovery, and
regeneration of the human body. For more information, visit http://secant.com/.

About ATVIO Biotech:

ATVIO Biotech, a wholly owned subsidiary of Masthercell Global, is a
leading global cell therapy process innovation center with a focus on
cGMP cell and gene manufacturing, virus manufacturing, process
development, custom automation and translation of cell therapies from
lab to market.

About Orgenesis

Orgenesis is a vertically-integrated biopharmaceutical company with
expertise and unique experience in cell therapy development and support
services. Through its Israeli subsidiary, Orgenesis Ltd., Orgenesis is
developing technology designed to successfully reprogram human liver
cells into glucose-responsive, fully functional, Insulin Producing Cells
(IPCs). Orgenesis believes that converting the diabetic patient's own
tissue into insulin-producing cells has the potential to overcome the
significant issues of donor shortage, cost and exposure to chronic
immunosuppressive therapy associated with islet cell transplantation.
Through its Masthercell Global subsidiary, a global contract development
and manufacturing organization (CDMO), Orgenesis is able to deliver
optimized process industrialization capacities to cell therapy
organizations and speed up the arrival of their therapies onto the
market. From technology selection to business modeling, GMP
manufacturing, process development, and quality management,
Masthercell's teams are fully committed to helping their clients fulfill
their objective of providing sustainable and affordable therapies to
their patients. Masthercell operates in a validated and flexible
facility located in the strategic center of Europe within the Walloon
healthcare cluster, Biowin. This integrated approach supports the
Company's business philosophy of bringing to market significant
life-improving medical treatments. For more information, visit www.orgenesis.com.

Notice Regarding Forward-Looking Statements

This press release contains forward-looking statements which are made
pursuant to the safe harbor provisions of Section 27A of the Securities
Act of 1933, as amended and Section 21E of the Securities and Exchange
Act of 1934, as amended. These forward-looking statements involve
substantial uncertainties and risks and are based upon our current
expectations, estimates and projections and reflect our beliefs and
assumptions based upon information available to us at the date of this
release.
We caution readers that forward-looking statements are
predictions based on our current expectations about future events.
These
forward-looking statements are not guarantees of future performance and
are subject to risks, uncertainties and assumptions that are difficult
to predict.
Our actual results, performance or achievements could
differ materially from those expressed or implied by the forward-looking
statements as a result of a number of factors, including, but not
limited to, the success of our reorganized CDMO operations, the success
of our partnership with Great Point, our ability to achieve and maintain
overall profitability, the sufficiency of working capital to realize our
business plans, the development of our transdifferentiation technology
as therapeutic treatment for diabetes which could, if successful, be a
cure for Type 1 Diabetes; our technology not functioning as expected;
our ability to retain key employees; our ability to satisfy the rigorous
regulatory requirements for new procedures; our competitors developing
better or cheaper alternatives to our products and the risks and
uncertainties discussed under the heading "RISK FACTORS" in Item 1A of
our Annual Report on Form 10-K for the fiscal year ended November 30,
2017, and in our other filings with the Securities and Exchange
Commission.
We undertake no obligation to revise or update any
forward-looking statement for any reason.

View Comments and Join the Discussion!